Brokerages Set Twist Bioscience Co. (NASDAQ:TWST) Price Target at $54.40

Shares of Twist Bioscience Co. (NASDAQ:TWST) have received a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $54.40.

TWST has been the subject of several research reports. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, February 4th. Barclays set a $58.00 price objective on shares of Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. Finally, Wolfe Research assumed coverage on shares of Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company.

Insider Buying and Selling at Twist Bioscience

In other news, Director Robert Chess sold 2,940 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $53.13, for a total value of $156,202.20. Following the completion of the sale, the director now directly owns 18,173 shares of the company’s stock, valued at $965,531.49. This represents a 13.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Paula Green sold 860 shares of the stock in a transaction on Friday, December 6th. The stock was sold at an average price of $52.70, for a total transaction of $45,322.00. Following the completion of the sale, the senior vice president now directly owns 133,715 shares of the company’s stock, valued at approximately $7,046,780.50. This trade represents a 0.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,676 shares of company stock valued at $1,640,289. Insiders own 3.01% of the company’s stock.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the company. Massachusetts Financial Services Co. MA increased its stake in shares of Twist Bioscience by 215.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after purchasing an additional 20,035 shares in the last quarter. Barclays PLC boosted its position in shares of Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after acquiring an additional 104,420 shares during the last quarter. FMR LLC boosted its position in shares of Twist Bioscience by 6.0% during the third quarter. FMR LLC now owns 218,561 shares of the company’s stock worth $9,875,000 after acquiring an additional 12,327 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Twist Bioscience during the fourth quarter worth $1,059,000. Finally, BNP Paribas Financial Markets boosted its position in shares of Twist Bioscience by 128.1% during the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock worth $1,718,000 after acquiring an additional 21,357 shares during the last quarter.

Twist Bioscience Trading Up 6.0 %

Shares of NASDAQ TWST opened at $42.05 on Thursday. The firm’s 50 day moving average price is $47.05 and its 200-day moving average price is $45.54. The company has a market cap of $2.51 billion, a PE ratio of -12.44 and a beta of 2.15. Twist Bioscience has a 52-week low of $27.41 and a 52-week high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. During the same period in the previous year, the company earned ($0.75) earnings per share. The firm’s quarterly revenue was up 24.1% on a year-over-year basis. On average, equities research analysts expect that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.